Drug Type Small molecule drug |
Synonyms UCB-5857 |
Target |
Mechanism PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (EU), Orphan Drug (US) |
Molecular FormulaC23H14ClF3N6O |
InChIKeyLNLJHGXOFYUARS-OAQYLSRUSA-N |
CAS Registry1362850-20-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Activated PI3K-delta Syndrome | Phase 3 | FR | 08 Jun 2016 | |
Primary Sjögren's syndrome | Phase 2 | FR | 01 Oct 2015 | |
Primary Sjögren's syndrome | Phase 2 | IT | 01 Oct 2015 | |
Primary Sjögren's syndrome | Phase 2 | ES | 01 Oct 2015 | |
Primary Sjögren's syndrome | Phase 2 | SE | 01 Oct 2015 | |
Primary Sjögren's syndrome | Phase 2 | GB | 01 Oct 2015 | |
Sjogren's Syndrome | Phase 2 | GR | - | |
Arthritis, Psoriatic | Phase 1 | GB | 01 Aug 2013 | |
Plaque psoriasis | Phase 1 | GB | - |
Phase 2 | 27 | ugpghgblqu(fqitgrrmfi): Difference = -2.59 (95% CI, 2.11 - 7.30), P-Value = 0.266 View more | Positive | 02 Mar 2021 | |||
Placebo | |||||||
Phase 2 | Primary Sjögren's syndrome EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) | 27 | jblyrzeraa(eibgdbdjie) = fiksibqtmo xbgsqedqpq (zskolmwgqo, 1.7) View more | Positive | 12 Jun 2019 | ||
Placebo | jblyrzeraa(eibgdbdjie) = gvdedarpqp xbgsqedqpq (zskolmwgqo, 1.5) View more | ||||||
Phase 1 | - | (90 mg QD) | lfswqpfdoi(fxgajzmrdy) = xvckkodfss pbfmzcnfyv (udgitjuayc ) | Positive | 01 May 2017 | ||
(30 mg BID) | lfswqpfdoi(fxgajzmrdy) = jsnworqiqp pbfmzcnfyv (udgitjuayc ) |